Display options
Cite
Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986;105(1):37-44doi: 10.7326/0003-4819-105-1-37.
Wharton, J. M., Coleman, D. L., Wofsy, C. B., Luce, J. M., Blumenfeld, W., Hadley, W. K., Ingram-Drake, L., Volberding, P. A., & Hopewell, P. C. (1986). Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Annals of internal medicine, 105(1), 37-44. https://doi.org/10.7326/0003-4819-105-1-37
Wharton, J M, et al. "Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial." Annals of internal medicine vol. 105,1 (1986): 37-44. doi: https://doi.org/10.7326/0003-4819-105-1-37
Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986 Jul;105(1):37-44. doi: 10.7326/0003-4819-105-1-37. PMID: 3521428.
Copy Download .nbib Format: NLM
Share it on
Full text links
Atypon

Ann Intern Med. 1986 Jul;105(1):37-44. doi: 10.7326/0003-4819-105-1-37.

Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Annals of internal medicine

J M Wharton, D L Coleman, C B Wofsy, J M Luce, W Blumenfeld, W K Hadley, L Ingram-Drake, P A Volberding, P C Hopewell

PMID: 3521428 DOI: 10.7326/0003-4819-105-1-37

Abstract

Forty patients with the acquired immunodeficiency syndrome (AIDS) and their first episodes of Pneumocystis carinii pneumonia were assigned at random to receive either trimethoprim-sulfamethoxazole or pentamidine isethionate. The two groups did not differ significantly in the severity of pulmonary or systemic processes at enrollment. Five patients treated initially with trimethoprim-sulfamethoxazole and one patient treated initially with pentamidine died during the 21-day treatment period (p = 0.09, Fisher's exact test). No significant differences were seen between groups in rates of improvement, pulmonary function tests, or 67Ga uptake by the lungs in the survivors at completion of therapy. Adverse reactions necessitated changing from the initial drug in 10 patients in the trimethoprim-sulfamethoxazole group and 11 in the pentamidine group. Minor reactions occurred in all patients. In patients with AIDS, trimethoprim-sulfamethoxazole and pentamidine do not have statistically significant differences in efficacy or frequency of adverse reactions.

Similar articles

Cited by

Iriart X, Bouar ML, Kamar N, Berry A.
J Fungi (Basel). 2015 Sep 28;1(3):293-331. doi: 10.3390/jof1030293.
PMID: 29376913

McDonald EG, Butler-Laporte G, Del Corpo O, Hsu JM, Lawandi A, Senecal J, Sohani ZN, Cheng MP, Lee TC.
Open Forum Infect Dis. 2021 Oct 29;8(12):ofab545. doi: 10.1093/ofid/ofab545. eCollection 2021 Dec.
PMID: 34988242

Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC.
Open Forum Infect Dis. 2020 Apr 02;7(5):ofaa112. doi: 10.1093/ofid/ofaa112. eCollection 2020 May.
PMID: 32391402

McDonald EG, Butler-Laporte G, Del Corpo O, Hsu JM, Lawandi A, Senecal J, Sohani ZN, Cheng MP, Lee TC.
Open Forum Infect Dis. 2021 Oct 29;8(12):ofab545. doi: 10.1093/ofid/ofab545. eCollection 2021 Dec.
PMID: 34988242

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources